ATC Group: N06BA Centrally acting sympathomimetics

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N06BA in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N06 Psychoanaleptics
3 N06B Psychostimulants, agents used for ADHD and nootropics
4 N06BA Centrally acting sympathomimetics

Group N06BA contents

Code Title
N06BA01 Amfetamine
N06BA02 Dexamfetamine
N06BA03 Metamfetamine
N06BA04 Methylphenidate
N06BA05 Pemoline
N06BA06 Fencamfamin
N06BA07 Modafinil
N06BA08 Fenozolone
N06BA09 Atomoxetine
N06BA10 Fenetylline
N06BA11
N06BA12
N06BA13
N06BA14
N06BA15

Active ingredients in N06BA

Active Ingredient Description
Amfetamine

Amphetamine is a potent central nervous system (CNS) stimulant that is used in the treatment of attention deficit hyperactivity disorder (ADHD), narcolepsy, and obesity. Amphetamine properly refers to a specific chemical, the racemic free base, which is equal parts of the two enantiomers, levoamphetamine and dextroamphetamine, in their pure amine forms. Historically, it has been used to treat nasal congestion and depression. Amphetamine is also used as an athletic performance enhancer and cognitive enhancer, and recreationally as an aphrodisiac and euphoriant.

Armodafinil

Armodafinil is an indirect dopamine receptor agonist; both armodafinil and modafinil bind in vitro to the dopamine transporter and inhibit dopamine reuptake. Armodafinil (R-modafinil) has pharmacological properties similar to those of modafinil (a mixture of R- and S-modafinil), to the extent tested in animal and in vitro studies.

Atomoxetine

Atomoxetine is a highly selective and potent inhibitor of the pre-synaptic noradrenaline transporter, its presumed mechanism of action, without directly affecting the serotonin or dopamine transporters.

Dexamfetamine

Amphetamines are non-catecholamine, sympathomimetic amines with CNS stimulant activity. Peripheral actions include elevations of systolic and diastolic blood pressures and weak bronchodilator and respiratory stimulant action.

Dexmethylphenidate

Dexmethylphenidate is a CNS stimulant. It is the more pharmacologically active d-enantiomer of racemic methylphenidate. Methylphenidate blocks the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space. The mode of therapeutic action in Attention Deficit Hyperactivity Disorder (ADHD) is not known.

Fencamfamin
Fenetylline
Lisdexamfetamine

Lisdexamfetamine is rapidly absorbed from the gastrointestinal tract and hydrolysed primarily by red blood cells to dexamfetamine, which is responsible for the drug’s activity. Amfetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity.

Metamfetamine

Methamphetamine is a sympathomimetic amine with CNS stimulant activity. Peripheral actions include elevation of systolic and diastolic blood pressures and weak bronchodilator and respiratory stimulant action.

Methylphenidate

Methylphenidate HCl is a mild central nervous system (CNS) stimulant. The mode of therapeutic action in Attention Deficit Hyperactivity Disorder (ADHD) is not known. Methylphenidate is thought to block the reuptake of noradrenaline and dopamine into the presynaptic neurone and increase the release of these monoamines into the extraneuronal space.

Modafinil

Modafinil promotes wakefulness in a variety of species, including man. The precise mechanism(s) through which modafinil promotes wakefulness is unknown.

Pemoline
Solriamfetol

Solriamfetol is indicated to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. Its mechanism of action has not been fully characterised. However, its efficacy could be mediated through its activity as a dopamine and norepinephrine (noradrenaline) reuptake inhibitor (DNRI).

Related product monographs

Title Information Source Document Type  
ADDERALL XR Extended-release capsule FDA, National Drug Code (US) MPI, US: SPL/PLR
AMFEXA Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
CONCERTA Extended-release tablet Medicines and Medical Devices Safety Authority (NZ) MPI, EU: SmPC
CONTRAMYL Prolonged release tablet Health Products Regulatory Authority (ZA) MPI, Generic
DELMOSART Prolonged-release tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
DEXEDRINE SPANSULE Extended-release capsule FDA, National Drug Code (US) MPI, US: SPL/Old
ELVANSE Capsule, hard Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
EQUASYM Modified release capsule, hard Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
FOCALIN Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
INIR Capsule Health Products Regulatory Authority (ZA) MPI, Generic
MATORIDE XR Prolonged-release tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
MEDIKINET Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
NUVIGIL Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
PROVIGIL Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
RADD Prolonged-release tablet Health Products Regulatory Authority (ZA) MPI, Generic
RITALIN Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
RUBIFEN Immediate release tablet, Sustained release tablet Medicines and Medical Devices Safety Authority (NZ) MPI, EU: SmPC
STRATTERA Capsule, hard Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
SUNOSI Filmโ€‘coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
VYVANSE Capsule / Tablet chewable FDA, National Drug Code (US) MPI, US: SPL/PLR